A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2011
10/11/2011	CA2438116C Amphoteric liposomes and the use thereof
10/11/2011	CA2424734C Nanoparticles comprising a metallic or semiconductor core which is covalently bound to a plurality of carbohydrate ligands
10/11/2011	CA2420537C A composition for treatment of parkinson's disease
10/11/2011	CA2402773C Tissue bulking and coating compositions
10/11/2011	CA2400482C Bupropion metabolites and methods of their synthesis and use
10/11/2011	CA2393410C Phosphonate compounds
10/11/2011	CA2390472C Anti-inflammatory actions of cytochrome p450 epoxygenase-derived eicosanoids
10/11/2011	CA2382177C Method of treating body insect infestation
10/11/2011	CA2336743C Antigenic peptides derived from telomerase
10/11/2011	CA2325442C Treatment of cardiac hypertrophy using interferon-gamma
10/11/2011	CA2247275C Use of rapamycin derivatives in vasculopathies and xenotransplantation
10/10/2011	CA2793975A1 Antibacterial isoquinolin-3-ylurea derivatives
10/06/2011	WO2011123863A1 Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs
10/06/2011	WO2011123856A1 Neuraminidase inhibitors
10/06/2011	WO2011123836A2 Pharmaceutical formulations for the treatment of overactive bladder
10/06/2011	WO2011123815A1 Methods of improving quality of sleep
10/06/2011	WO2011123767A1 Method of treating inflammation
10/06/2011	WO2011123751A2 Heterocyclic compounds and their uses
10/06/2011	WO2011123719A2 Use of faah inhibitors for treating abdominal, visceral and pelvic pain
10/06/2011	WO2011123693A1 Sweet flavor modifier
10/06/2011	WO2011123691A1 Perifosine and capecitabine as a combined treatment for cancer
10/06/2011	WO2011123681A1 Methods for using carboxamide, sulfonamide and amine compounds
10/06/2011	WO2011123678A2 Substituted benzo-pyrido-triazolo-diazepine compounds
10/06/2011	WO2011123674A1 Compounds for treating neurodegenerative diseases
10/06/2011	WO2011123672A1 Purine nucleoside phosphoramidate
10/06/2011	WO2011123654A1 Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
10/06/2011	WO2011123645A2 Nucleoside phosphoramidates
10/06/2011	WO2011123641A1 Solid state forms of sitagliptin salts
10/06/2011	WO2011123619A2 Permeable mixtures, methods and compositions for the skin
10/06/2011	WO2011123609A1 Imidazolyl-imidazoles as kinase inhibitors
10/06/2011	WO2011123591A1 Injectable dendrimer hydrogel nanoparticles
10/06/2011	WO2011123586A1 Compounds and pharmaceutical compositions for the treatment of viral infections
10/06/2011	WO2011123536A1 Polycyclic tetracycline compounds
10/06/2011	WO2011123524A2 Macrolide inhibitors of mtor
10/06/2011	WO2011123518A1 Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
10/06/2011	WO2011123499A1 Hypersulfated glucopyranosides
10/06/2011	WO2011123496A1 Formulations of mazindol
10/06/2011	WO2011123493A1 Substituted pyrrolotriazines as protein kinase inhibitors
10/06/2011	WO2011123482A1 Purine compounds used as cb2 agonists
10/06/2011	WO2011123468A1 Sirna therapy for transthyretin (ttr) related ocular amyloidosis
10/06/2011	WO2011123427A2 Treatment of cancer by inhibiting activity or expression of late sv-40 factor
10/06/2011	WO2011123401A1 Uses of dgat1 inhibitors
10/06/2011	WO2011123395A1 Methods of treating cancer
10/06/2011	WO2011123393A1 Methods of enhancing drug delivery and effectiveness of therapeutic agents
10/06/2011	WO2011123372A1 Purine compounds
10/06/2011	WO2011123236A1 D-tagatose and biguanide compositions and methods
10/06/2011	WO2011123232A1 Cgrp receptor antagonist
10/06/2011	WO2011123084A1 Opioid receptor antagonist (naltrexone) for use in treating herpes zoster disease
10/06/2011	WO2011123042A1 Vaccination procedure and products for use therein
10/06/2011	WO2011123027A1 Improved treatment of renal cell carcinoma
10/06/2011	WO2011122991A1 Indole derivative with antihypertensive effect and method for producing same
10/06/2011	WO2011122978A1 Method for eliminating gardnerella vaginalis and atopobium vaginae bacteria in bacterial vaginosis
10/06/2011	WO2011122916A2 Composition for increasing trail sensitivity, containing an inhibitor for inhibiting the expression or activity of tip41 which is a trail sensitizer target gene
10/06/2011	WO2011122899A2 Pharmaceutical composition for inhibiting platelet aggregation or for thrombolysis
10/06/2011	WO2011122815A2 Novel quinoxaline derivatives
10/06/2011	WO2011122701A1 Method for treating schizophrenia and related diseases
10/06/2011	WO2011122634A1 Prognostic method for pulmonary adenocarcinoma, pulmonary adenocarcinoma detection kit, and pharmaceutical composition for treating pulmonary adenocarcinoma
10/06/2011	WO2011122620A1 Pharmaceutical preparation comprising phenylalanine derivative
10/06/2011	WO2011122619A1 Phenylalanine derivative salt crystal
10/06/2011	WO2011122524A1 Controlled release pharmaceutical composition
10/06/2011	WO2011122523A1 Controlled release pharmaceutical composition
10/06/2011	WO2011122477A1 Vesicle-containing composition
10/06/2011	WO2011122468A1 Pyripyropene derivative having acat2 inhibiting activity and stable to metabolizing enzymes
10/06/2011	WO2011122458A1 Aromatic ring compound containing nitrogen
10/06/2011	WO2011122389A1 Oil and fat composition for prevention or treatment of diabetes
10/06/2011	WO2011122321A1 Agent for inhibiting physiological activity of heparin-binding protein
10/06/2011	WO2011122041A1 Expression modulator for clock gene period
10/06/2011	WO2011121824A1 Orally disintegrating tablet
10/06/2011	WO2011121823A1 Particulate pharmaceutical composition for oral administration
10/06/2011	WO2011121645A1 Amyloid fibril formation inhibitor
10/06/2011	WO2011121629A1 Indolic derivatives and use thereof in medical field
10/06/2011	WO2011121607A2 Rasagiline and its pharmaceutically acceptable salts
10/06/2011	WO2011121597A1 A PROCESS FOR THE PREPARATION OF 5-SUBSTITUTED 3-(5-NITRO-4-THIOCYANATOPYRIMIDIN-2-YL)-3H-BENZO [d]-IMIDAZOLE
10/06/2011	WO2011121593A1 Stable pharmaceutical composition of imatinib
10/06/2011	WO2011121558A1 Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer
10/06/2011	WO2011121555A1 Antibacterial isoquinolin-3-ylurea derivatives
10/06/2011	WO2011121505A1 Cytokine inhibitors
10/06/2011	WO2011121453A2 Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
10/06/2011	WO2011121434A1 NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY
10/06/2011	WO2011121418A1 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists
10/06/2011	WO2011121366A1 Pyrazole p38 map kinase inhibitors
10/06/2011	WO2011121357A2 Transcription factor decoys
10/06/2011	WO2011121351A1 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
10/06/2011	WO2011121350A1 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors
10/06/2011	WO2011121345A1 Novel combination and use
10/06/2011	WO2011121317A1 Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
10/06/2011	WO2011121309A1 Phenyl sulfonyl derivatives and their use as histamine h3 antagonists
10/06/2011	WO2011121308A1 New polymorph
10/06/2011	WO2011121305A2 Method for preserving alum adjuvants and alum-adjuvanted vaccines
10/06/2011	WO2011121289A2 Compounds and their use
10/06/2011	WO2011121223A1 6-(alkyl- or cycloalkyl-triazolopyridazine-sulfanyl) benzothiazole derivatives: preparation, application as medicaments and use as met inhibitors
10/06/2011	WO2011121182A1 Pharmaceutical composition comprising gemfibrozil and cyp2c8 and/or oatp substrate drug such as repaglinide
10/06/2011	WO2011121162A1 Use of valproic acid as an antiviral agent against enveloped viruses
10/06/2011	WO2011121161A1 New ammonium phenoxide dendrimers having a carbosilane structure and uses thereof
10/06/2011	WO2011121160A1 Pharmaceutical formulation based on ibuprofen and codeine having having improved stability
10/06/2011	WO2011121151A1 Functional food supplement intended, in particular, for nutrition and for prevention and improvement in cases of neurological alterations, neurodegenerative alterations or cognitive disorders
10/06/2011	WO2011121150A1 Enteral or oral food product intended, in particular, for nutrition and for the prevention and improvement of neurological alterations, neurodegenerative alterations or cognitive disorders
10/06/2011	WO2011121137A1 Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
10/06/2011	WO2011121120A1 ANTAGONISTS OF miRNA-29 EXPRESSION AND THEIR USE IN THE PREVENTION AND TREATMENT OF AORTIC ANEURYSMS
10/06/2011	WO2011121109A1 Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)

1 ... 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 ... 7860